Forward Science has introduced SalivaCaine, a prescription oral rinse with many of the same ingredients as SalivaMax as well as benzocaine for temporary oral pain relief.
Since being founded in 2012, Forward Science has expanded its product portfolio, focusing on early discovery, diagnostics, and treatment options for the oral oncology market. In February 2016, the company launched SalivaMax, an FDA-approved prescription rinse for xerostomia and mucositis. SalivaMax is a product that can be used during cancer treatments in which a common side effect is oral mucositis. Although SalivaMax can shorten the duration and severity of mucositis for those undergoing cancer treatment, some patients have an acute need for pain relief while on the SalivaMax regimen.SalivaMax typically takes a few days to achieve its full potential, slowly replenishing the essential ions that are lost with lack of saliva and treating the root cause of xerostomia and/or mucositis. In the few days it takes to become effective, cancer patients can sometimes experience oral pain during their treatment course. Forward Science's research and development team created SalivaCaine for this need. SalivaCaine has many of the same ingredients as SalivaMax, plus benzocaine for temporary oral pain relief.
SalivaMax and SalivaCaine can be used in combination by anyone who is undergoing cancer treatment. SalivaCaine is used to relieve the pain at the same time SalivaMax is used to treat the root cause of the problem. SalivaCaine is provided free with any SalivaMax prescription.
To receive samples or a free prescription form, contact Forward Science at (855) 696-7254 or ForwardScience.com/SalivaCaine.
